RxDoctor Payments Data

Sheldon Kaplan

Pediatric Infectious Diseases · Houston, TXNPI 1982784245

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.4% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Merck at 46.0% of the total.

$578in general payments, 2019–2025

Across 24 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$266
  • Astellas Pharma US Inc$234
  • AbbVie$78
$1,821,522in research payments, 2019–2025

Across 37 payments — averaging $49,230 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.6M
  • AbbVie$138K
  • Merck$48K

What the payments were for

  • Food & beverage$53492%
  • Education$448%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck12$266
Astellas Pharma US Inc9$234
AbbVie3$78

How this compares

$578 in reported general payments places this provider in the 65th percentile of 66 pediatric infectious diseases providers in Texas.

See all pediatric infectious diseases providers in Texas

Other pediatric infectious diseases in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →